Hope Ignited: FDA Backs Key to Unlock New Lung Cancer Therapy!

FDA greenlights Roche's VENTANA MET assay, a pioneering diagnostic for non-squamous NSCLC.
This test pinpoints patients with high MET protein, making them eligible for AbbVie's Emrelis.
Offers new hope by enabling personalized treatment for a devastating disease often diagnosed late.

In the relentless battle against non-small cell lung cancer (NSCLC), a formidable foe that remains the world's leading cause of cancer deaths^{4, 5}, a beacon of hope has emerged. Roche has announced a pivotal FDA approval for its VENTANA® MET (SP44) RxDx Assay – the first companion diagnostic of its kind. This breakthrough tool is set to revolutionize how doctors identify non-squamous NSCLC patients who could benefit from AbbVie’s targeted therapy, Emrelis™ (telisotuzumab vedotin-tllv).

For too long, advanced NSCLC patients, especially those with normal EGFR genes where roughly a quarter exhibit high MET protein levels¹, faced grim prognoses with limited treatment options. The MET pathway, a key player in how these cancers grow and resist treatment¹, has been a challenging target. Now, this new assay precisely detects MET protein expression. "Understanding the molecular drivers...is critical," stated Matt Sause, CEO of Roche Diagnostics, emphasizing the power to offer "timely, tailored treatment options that may improve patient outcomes."

The approval, supported by the LUMINOSITY study, showed that patients with high c-Met protein expression treated with Emrelis achieved a 35% overall response rate and a median duration of response of 7.2 months⁸. This isn't just a test; it's a crucial key, unlocking personalized therapy and offering a chance to rewrite the narrative for those facing this challenging disease.

Hope Ignited: FDA Backs Key to Unlock New Lung Cancer Therapy!

References

Stay Updated!